Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud's phenomenon in patients with systemic sclerosis: a double blind randomised study

OBJECTIVE--To compare the long term effects of short term intravenous infusions of iloprost with those of oral nifedipine in patients with Raynaud's phenomenon associated with systemic sclerosis. DESIGN--Double blind, placebo controlled, randomised group comparison. SETTING--Dermatology outpati...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:BMJ 1989-03, Vol.298 (6673), p.561-564
Hauptverfasser: Rademaker, M., Cooke, E. D., Almond, N. E., Beacham, J. A., Smith, R. E., Mant, T. G., Kirby, J. D.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 564
container_issue 6673
container_start_page 561
container_title BMJ
container_volume 298
creator Rademaker, M.
Cooke, E. D.
Almond, N. E.
Beacham, J. A.
Smith, R. E.
Mant, T. G.
Kirby, J. D.
description OBJECTIVE--To compare the long term effects of short term intravenous infusions of iloprost with those of oral nifedipine in patients with Raynaud's phenomenon associated with systemic sclerosis. DESIGN--Double blind, placebo controlled, randomised group comparison. SETTING--Dermatology outpatient clinic. PATIENTS--Twenty three patients with Raynaud's phenomenon associated with well documented systemic sclerosis (American Rheumatism Association criteria) and with typical abnormalities in fingernail folds on capillaroscopy. INTERVENTIONS--Twelve patients were randomised to receive intravenous infusions of iloprost starting at 0.5 ng/kg/min and increased by 0.5 ng/kg/min every 15 minutes to a maximum of 2.0 ng/kg/min for eight hours on three consecutive days with a further single infusion at week 8. Placebo capsules were given concurrently. Eleven patients were randomised to receive nifedipine, starting at 30 mg daily and increased to 60 mg daily after four weeks for another 12 weeks. Infusions of placebo were given in the same manner as the infusions of iloprost. One patient from each group withdrew because of social reasons and three patients receiving nifedipine withdrew because of side effects. END POINT--Reduction in number, duration, and severity of attacks of Raynaud's phenomenon, reduction in number of digital lesions, increase in digital blood flow. MEASUREMENTS AND MAIN RESULTS--Measurements were taken at 0, 4, 8, 12, and 16 weeks. Both regimens produced a reduction in the number, duration, and severity of attacks of Raynaud's phenomenon. The mean (SE) number of digital lesions was reduced with iloprost (from 3.5 (1.6) to 0.6 (0.3] and with nifedipine (from 4.3 (0.8) to 1.4 (0.5] after 16 weeks. Hand temperature and digital and microcirculatory blood flow were increased with iloprost but not with nifedipine. CONCLUSION--Both iloprost and nifedipine are beneficial in the treatment of Raynaud's phenomenon. With nifedipine, however, side effects are common. Short term infusions of iloprost provide longlasting relief of symptoms, and side effects occur only during the infusions and are dose dependent.
doi_str_mv 10.1136/bmj.298.6673.561
format Article
fullrecord <record><control><sourceid>jstor_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1835951</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><jstor_id>29702454</jstor_id><sourcerecordid>29702454</sourcerecordid><originalsourceid>FETCH-LOGICAL-b541t-bef63cd3e0518a549bd77b52cea5eec0603bde762193dfc2cb76708a48aac0863</originalsourceid><addsrcrecordid>eNqFUU1v1DAUjBCorErvXJAsceCAsthx_BEOSGhFKaICUQHiZjmxw3pJ7GA7bfdH8R95y662cOJkyzNvZvymKB4TvCSE8hftuFlWjVxyLuiScXKvWJCay5JJSu8XC9ywppSEyofFWUobjHFFhWw4OylOqpoLQcii-LUK46SjS8Gj0CPnc9TX1oc5wb2fkws-_QGGMMWQMtLeoBD1gLzrrXGT8xaYKEer82h93pGv9Nbr2TxLaFqDFjyDOpAmnR1QErpxeY3SNmU7ug6lbrCg7dJLpJEJcztY1A4OjCK4hdEla1DKs9k-Kh70ekj27HCeFl_O33xeXZSXH9--W72-LFtWk1y2tue0M9RiRqRmddMaIVpWdVYzazvMMW2NFbwiDTV9V3Wt4AJLXUutOyw5PS1e7XWnuR2t6exuLYOaoht13KqgnfoX8W6tvodrRSRlDSMg8PQgEMPP2aasNmGOHjIrIgSvSSMqASy8Z3Xw_RRtf3QgWO0qVlCxgorVrmIFFcPIk7-THQcOhd7hm5RDvIMbgaua1YCXe9zB8m-PuI4_FFgIpj58Xamrb-zifX3-SUngP9_zd0n-m-433hPO9A</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1776419727</pqid></control><display><type>article</type><title>Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud's phenomenon in patients with systemic sclerosis: a double blind randomised study</title><source>MEDLINE</source><source>Jstor Complete Legacy</source><source>Alma/SFX Local Collection</source><creator>Rademaker, M. ; Cooke, E. D. ; Almond, N. E. ; Beacham, J. A. ; Smith, R. E. ; Mant, T. G. ; Kirby, J. D.</creator><creatorcontrib>Rademaker, M. ; Cooke, E. D. ; Almond, N. E. ; Beacham, J. A. ; Smith, R. E. ; Mant, T. G. ; Kirby, J. D.</creatorcontrib><description>OBJECTIVE--To compare the long term effects of short term intravenous infusions of iloprost with those of oral nifedipine in patients with Raynaud's phenomenon associated with systemic sclerosis. DESIGN--Double blind, placebo controlled, randomised group comparison. SETTING--Dermatology outpatient clinic. PATIENTS--Twenty three patients with Raynaud's phenomenon associated with well documented systemic sclerosis (American Rheumatism Association criteria) and with typical abnormalities in fingernail folds on capillaroscopy. INTERVENTIONS--Twelve patients were randomised to receive intravenous infusions of iloprost starting at 0.5 ng/kg/min and increased by 0.5 ng/kg/min every 15 minutes to a maximum of 2.0 ng/kg/min for eight hours on three consecutive days with a further single infusion at week 8. Placebo capsules were given concurrently. Eleven patients were randomised to receive nifedipine, starting at 30 mg daily and increased to 60 mg daily after four weeks for another 12 weeks. Infusions of placebo were given in the same manner as the infusions of iloprost. One patient from each group withdrew because of social reasons and three patients receiving nifedipine withdrew because of side effects. END POINT--Reduction in number, duration, and severity of attacks of Raynaud's phenomenon, reduction in number of digital lesions, increase in digital blood flow. MEASUREMENTS AND MAIN RESULTS--Measurements were taken at 0, 4, 8, 12, and 16 weeks. Both regimens produced a reduction in the number, duration, and severity of attacks of Raynaud's phenomenon. The mean (SE) number of digital lesions was reduced with iloprost (from 3.5 (1.6) to 0.6 (0.3] and with nifedipine (from 4.3 (0.8) to 1.4 (0.5] after 16 weeks. Hand temperature and digital and microcirculatory blood flow were increased with iloprost but not with nifedipine. CONCLUSION--Both iloprost and nifedipine are beneficial in the treatment of Raynaud's phenomenon. With nifedipine, however, side effects are common. Short term infusions of iloprost provide longlasting relief of symptoms, and side effects occur only during the infusions and are dose dependent.</description><identifier>ISSN: 0959-8138</identifier><identifier>EISSN: 1468-5833</identifier><identifier>EISSN: 1756-1833</identifier><identifier>DOI: 10.1136/bmj.298.6673.561</identifier><identifier>PMID: 2467711</identifier><language>eng</language><publisher>England: British Medical Journal Publishing Group</publisher><subject>Administration, Oral ; Blood flow ; Capsules ; Clinical Trials as Topic ; Dosage ; Dose-Response Relationship, Drug ; Double-Blind Method ; Epoprostenol - administration &amp; dosage ; Epoprostenol - adverse effects ; Epoprostenol - therapeutic use ; Female ; Forearm ; Hemodynamics - drug effects ; Humans ; Iloprost ; Infusions, Intravenous ; Intravenous infusions ; Lesions ; Male ; Nifedipine - administration &amp; dosage ; Nifedipine - adverse effects ; Nifedipine - therapeutic use ; Placebos ; Random Allocation ; Raynaud disease ; Raynaud Disease - drug therapy ; Raynaud Disease - physiopathology ; Regional Blood Flow - drug effects ; Scleroderma, Systemic - complications ; Side effects ; Systemic scleroderma</subject><ispartof>BMJ, 1989-03, Vol.298 (6673), p.561-564</ispartof><rights>Copyright 1989 British Medical Journal</rights><rights>Copyright BMJ Publishing Group LTD Mar 4, 1989</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b541t-bef63cd3e0518a549bd77b52cea5eec0603bde762193dfc2cb76708a48aac0863</citedby><cites>FETCH-LOGICAL-b541t-bef63cd3e0518a549bd77b52cea5eec0603bde762193dfc2cb76708a48aac0863</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.jstor.org/stable/pdf/29702454$$EPDF$$P50$$Gjstor$$H</linktopdf><linktohtml>$$Uhttps://www.jstor.org/stable/29702454$$EHTML$$P50$$Gjstor$$H</linktohtml><link.rule.ids>230,314,777,781,800,882,27905,27906,57998,58231</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/2467711$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Rademaker, M.</creatorcontrib><creatorcontrib>Cooke, E. D.</creatorcontrib><creatorcontrib>Almond, N. E.</creatorcontrib><creatorcontrib>Beacham, J. A.</creatorcontrib><creatorcontrib>Smith, R. E.</creatorcontrib><creatorcontrib>Mant, T. G.</creatorcontrib><creatorcontrib>Kirby, J. D.</creatorcontrib><title>Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud's phenomenon in patients with systemic sclerosis: a double blind randomised study</title><title>BMJ</title><addtitle>BMJ</addtitle><description>OBJECTIVE--To compare the long term effects of short term intravenous infusions of iloprost with those of oral nifedipine in patients with Raynaud's phenomenon associated with systemic sclerosis. DESIGN--Double blind, placebo controlled, randomised group comparison. SETTING--Dermatology outpatient clinic. PATIENTS--Twenty three patients with Raynaud's phenomenon associated with well documented systemic sclerosis (American Rheumatism Association criteria) and with typical abnormalities in fingernail folds on capillaroscopy. INTERVENTIONS--Twelve patients were randomised to receive intravenous infusions of iloprost starting at 0.5 ng/kg/min and increased by 0.5 ng/kg/min every 15 minutes to a maximum of 2.0 ng/kg/min for eight hours on three consecutive days with a further single infusion at week 8. Placebo capsules were given concurrently. Eleven patients were randomised to receive nifedipine, starting at 30 mg daily and increased to 60 mg daily after four weeks for another 12 weeks. Infusions of placebo were given in the same manner as the infusions of iloprost. One patient from each group withdrew because of social reasons and three patients receiving nifedipine withdrew because of side effects. END POINT--Reduction in number, duration, and severity of attacks of Raynaud's phenomenon, reduction in number of digital lesions, increase in digital blood flow. MEASUREMENTS AND MAIN RESULTS--Measurements were taken at 0, 4, 8, 12, and 16 weeks. Both regimens produced a reduction in the number, duration, and severity of attacks of Raynaud's phenomenon. The mean (SE) number of digital lesions was reduced with iloprost (from 3.5 (1.6) to 0.6 (0.3] and with nifedipine (from 4.3 (0.8) to 1.4 (0.5] after 16 weeks. Hand temperature and digital and microcirculatory blood flow were increased with iloprost but not with nifedipine. CONCLUSION--Both iloprost and nifedipine are beneficial in the treatment of Raynaud's phenomenon. With nifedipine, however, side effects are common. Short term infusions of iloprost provide longlasting relief of symptoms, and side effects occur only during the infusions and are dose dependent.</description><subject>Administration, Oral</subject><subject>Blood flow</subject><subject>Capsules</subject><subject>Clinical Trials as Topic</subject><subject>Dosage</subject><subject>Dose-Response Relationship, Drug</subject><subject>Double-Blind Method</subject><subject>Epoprostenol - administration &amp; dosage</subject><subject>Epoprostenol - adverse effects</subject><subject>Epoprostenol - therapeutic use</subject><subject>Female</subject><subject>Forearm</subject><subject>Hemodynamics - drug effects</subject><subject>Humans</subject><subject>Iloprost</subject><subject>Infusions, Intravenous</subject><subject>Intravenous infusions</subject><subject>Lesions</subject><subject>Male</subject><subject>Nifedipine - administration &amp; dosage</subject><subject>Nifedipine - adverse effects</subject><subject>Nifedipine - therapeutic use</subject><subject>Placebos</subject><subject>Random Allocation</subject><subject>Raynaud disease</subject><subject>Raynaud Disease - drug therapy</subject><subject>Raynaud Disease - physiopathology</subject><subject>Regional Blood Flow - drug effects</subject><subject>Scleroderma, Systemic - complications</subject><subject>Side effects</subject><subject>Systemic scleroderma</subject><issn>0959-8138</issn><issn>1468-5833</issn><issn>1756-1833</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1989</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqFUU1v1DAUjBCorErvXJAsceCAsthx_BEOSGhFKaICUQHiZjmxw3pJ7GA7bfdH8R95y662cOJkyzNvZvymKB4TvCSE8hftuFlWjVxyLuiScXKvWJCay5JJSu8XC9ywppSEyofFWUobjHFFhWw4OylOqpoLQcii-LUK46SjS8Gj0CPnc9TX1oc5wb2fkws-_QGGMMWQMtLeoBD1gLzrrXGT8xaYKEer82h93pGv9Nbr2TxLaFqDFjyDOpAmnR1QErpxeY3SNmU7ug6lbrCg7dJLpJEJcztY1A4OjCK4hdEla1DKs9k-Kh70ekj27HCeFl_O33xeXZSXH9--W72-LFtWk1y2tue0M9RiRqRmddMaIVpWdVYzazvMMW2NFbwiDTV9V3Wt4AJLXUutOyw5PS1e7XWnuR2t6exuLYOaoht13KqgnfoX8W6tvodrRSRlDSMg8PQgEMPP2aasNmGOHjIrIgSvSSMqASy8Z3Xw_RRtf3QgWO0qVlCxgorVrmIFFcPIk7-THQcOhd7hm5RDvIMbgaua1YCXe9zB8m-PuI4_FFgIpj58Xamrb-zifX3-SUngP9_zd0n-m-433hPO9A</recordid><startdate>19890304</startdate><enddate>19890304</enddate><creator>Rademaker, M.</creator><creator>Cooke, E. D.</creator><creator>Almond, N. E.</creator><creator>Beacham, J. A.</creator><creator>Smith, R. E.</creator><creator>Mant, T. G.</creator><creator>Kirby, J. D.</creator><general>British Medical Journal Publishing Group</general><general>British Medical Association</general><general>BMJ Publishing Group LTD</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88I</scope><scope>8AF</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ASE</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FPQ</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K6X</scope><scope>K9.</scope><scope>LK8</scope><scope>M2O</scope><scope>M2P</scope><scope>M7P</scope><scope>MBDVC</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>5PM</scope></search><sort><creationdate>19890304</creationdate><title>Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud's phenomenon in patients with systemic sclerosis: a double blind randomised study</title><author>Rademaker, M. ; Cooke, E. D. ; Almond, N. E. ; Beacham, J. A. ; Smith, R. E. ; Mant, T. G. ; Kirby, J. D.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b541t-bef63cd3e0518a549bd77b52cea5eec0603bde762193dfc2cb76708a48aac0863</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1989</creationdate><topic>Administration, Oral</topic><topic>Blood flow</topic><topic>Capsules</topic><topic>Clinical Trials as Topic</topic><topic>Dosage</topic><topic>Dose-Response Relationship, Drug</topic><topic>Double-Blind Method</topic><topic>Epoprostenol - administration &amp; dosage</topic><topic>Epoprostenol - adverse effects</topic><topic>Epoprostenol - therapeutic use</topic><topic>Female</topic><topic>Forearm</topic><topic>Hemodynamics - drug effects</topic><topic>Humans</topic><topic>Iloprost</topic><topic>Infusions, Intravenous</topic><topic>Intravenous infusions</topic><topic>Lesions</topic><topic>Male</topic><topic>Nifedipine - administration &amp; dosage</topic><topic>Nifedipine - adverse effects</topic><topic>Nifedipine - therapeutic use</topic><topic>Placebos</topic><topic>Random Allocation</topic><topic>Raynaud disease</topic><topic>Raynaud Disease - drug therapy</topic><topic>Raynaud Disease - physiopathology</topic><topic>Regional Blood Flow - drug effects</topic><topic>Scleroderma, Systemic - complications</topic><topic>Side effects</topic><topic>Systemic scleroderma</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rademaker, M.</creatorcontrib><creatorcontrib>Cooke, E. D.</creatorcontrib><creatorcontrib>Almond, N. E.</creatorcontrib><creatorcontrib>Beacham, J. A.</creatorcontrib><creatorcontrib>Smith, R. E.</creatorcontrib><creatorcontrib>Mant, T. G.</creatorcontrib><creatorcontrib>Kirby, J. D.</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Index</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>British Nursing Index (BNI) (1985 to Present)</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>British Nursing Index</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>BMJ</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rademaker, M.</au><au>Cooke, E. D.</au><au>Almond, N. E.</au><au>Beacham, J. A.</au><au>Smith, R. E.</au><au>Mant, T. G.</au><au>Kirby, J. D.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud's phenomenon in patients with systemic sclerosis: a double blind randomised study</atitle><jtitle>BMJ</jtitle><addtitle>BMJ</addtitle><date>1989-03-04</date><risdate>1989</risdate><volume>298</volume><issue>6673</issue><spage>561</spage><epage>564</epage><pages>561-564</pages><issn>0959-8138</issn><eissn>1468-5833</eissn><eissn>1756-1833</eissn><abstract>OBJECTIVE--To compare the long term effects of short term intravenous infusions of iloprost with those of oral nifedipine in patients with Raynaud's phenomenon associated with systemic sclerosis. DESIGN--Double blind, placebo controlled, randomised group comparison. SETTING--Dermatology outpatient clinic. PATIENTS--Twenty three patients with Raynaud's phenomenon associated with well documented systemic sclerosis (American Rheumatism Association criteria) and with typical abnormalities in fingernail folds on capillaroscopy. INTERVENTIONS--Twelve patients were randomised to receive intravenous infusions of iloprost starting at 0.5 ng/kg/min and increased by 0.5 ng/kg/min every 15 minutes to a maximum of 2.0 ng/kg/min for eight hours on three consecutive days with a further single infusion at week 8. Placebo capsules were given concurrently. Eleven patients were randomised to receive nifedipine, starting at 30 mg daily and increased to 60 mg daily after four weeks for another 12 weeks. Infusions of placebo were given in the same manner as the infusions of iloprost. One patient from each group withdrew because of social reasons and three patients receiving nifedipine withdrew because of side effects. END POINT--Reduction in number, duration, and severity of attacks of Raynaud's phenomenon, reduction in number of digital lesions, increase in digital blood flow. MEASUREMENTS AND MAIN RESULTS--Measurements were taken at 0, 4, 8, 12, and 16 weeks. Both regimens produced a reduction in the number, duration, and severity of attacks of Raynaud's phenomenon. The mean (SE) number of digital lesions was reduced with iloprost (from 3.5 (1.6) to 0.6 (0.3] and with nifedipine (from 4.3 (0.8) to 1.4 (0.5] after 16 weeks. Hand temperature and digital and microcirculatory blood flow were increased with iloprost but not with nifedipine. CONCLUSION--Both iloprost and nifedipine are beneficial in the treatment of Raynaud's phenomenon. With nifedipine, however, side effects are common. Short term infusions of iloprost provide longlasting relief of symptoms, and side effects occur only during the infusions and are dose dependent.</abstract><cop>England</cop><pub>British Medical Journal Publishing Group</pub><pmid>2467711</pmid><doi>10.1136/bmj.298.6673.561</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0959-8138
ispartof BMJ, 1989-03, Vol.298 (6673), p.561-564
issn 0959-8138
1468-5833
1756-1833
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1835951
source MEDLINE; Jstor Complete Legacy; Alma/SFX Local Collection
subjects Administration, Oral
Blood flow
Capsules
Clinical Trials as Topic
Dosage
Dose-Response Relationship, Drug
Double-Blind Method
Epoprostenol - administration & dosage
Epoprostenol - adverse effects
Epoprostenol - therapeutic use
Female
Forearm
Hemodynamics - drug effects
Humans
Iloprost
Infusions, Intravenous
Intravenous infusions
Lesions
Male
Nifedipine - administration & dosage
Nifedipine - adverse effects
Nifedipine - therapeutic use
Placebos
Random Allocation
Raynaud disease
Raynaud Disease - drug therapy
Raynaud Disease - physiopathology
Regional Blood Flow - drug effects
Scleroderma, Systemic - complications
Side effects
Systemic scleroderma
title Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud's phenomenon in patients with systemic sclerosis: a double blind randomised study
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-18T09%3A56%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-jstor_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Comparison%20of%20intravenous%20infusions%20of%20iloprost%20and%20oral%20nifedipine%20in%20treatment%20of%20Raynaud's%20phenomenon%20in%20patients%20with%20systemic%20sclerosis:%20a%20double%20blind%20randomised%20study&rft.jtitle=BMJ&rft.au=Rademaker,%20M.&rft.date=1989-03-04&rft.volume=298&rft.issue=6673&rft.spage=561&rft.epage=564&rft.pages=561-564&rft.issn=0959-8138&rft.eissn=1468-5833&rft_id=info:doi/10.1136/bmj.298.6673.561&rft_dat=%3Cjstor_pubme%3E29702454%3C/jstor_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1776419727&rft_id=info:pmid/2467711&rft_jstor_id=29702454&rfr_iscdi=true